ALLO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Allogene Therapeutics Inc (ALLO) is not a strong buy at this time for a beginner investor with a long-term strategy. Despite some positive catalysts such as recent analyst upgrades and potential future sales growth, the company's weak financial performance, lack of strong trading signals, and current negative price momentum make it a less favorable investment option right now. Holding off until clearer positive trends emerge may be prudent.
The MACD is slightly positive and contracting, indicating weak bullish momentum. RSI is neutral at 43.55, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock closed below its pivot level (2.419), suggesting bearish sentiment in the short term. Key support levels are at 2.118 and 1.931, while resistance levels are at 2.721 and 2.908.
Analysts have recently upgraded the stock with price targets of $5 and $8, citing confidence in clinical success and potential for $1B peak sales by
Upcoming Q4 2025 earnings report and investor webcast on March 12, 2026, could provide updates on advancements in cancer and autoimmune disease treatments.
The stock experienced a significant regular market drop of -8.70%, indicating bearish sentiment.
Financial performance is weak, with net income and EPS dropping significantly YoY in Q3
No significant hedge fund or insider trading trends, and no recent congress trading data.
In Q3 2025, revenue remained at $0, net income dropped by -37.55% YoY to -$41.4M, EPS declined by -40.62% YoY to -0.19, and gross margin fell to 0. These figures highlight poor financial health and lack of profitability.
Recent analyst upgrades include Citizens upgrading to Outperform with a $5 price target and UBS initiating coverage with a Buy rating and $8 price target. Analysts are optimistic about the company's clinical progress and long-term sales potential.
